NCT03513562View on ClinicalTrials.gov

Venetoclax and Ibrutinib in Treating in Participants with Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

March 26, 2019

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Chronic Lymphocytic LeukemiaIbrutinib Resistance
Interventions
DRUG

Ibrutinib

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Venetoclax

Given PO

Trial Locations (1)

43210

Ohio State University Comprehensive Cancer Center, Columbus

All Listed Sponsors
lead

Ohio State University Comprehensive Cancer Center

OTHER